Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology

Gianfranco Ferracioli, Maria De Santis, Barbara Tolusso

Research output: Contribution to journalArticlepeer-review


Genomic medicine has raised many expectations with regard to individualized therapies. Drug response is a complex function of many genes interacting with environmental and behavioral factors. In addition, poor prescribing, interactions between drugs and an incomplete understanding of the metabolism of many drugs, which are administered simultaneously to treat concomitant morbidities, are leading causes of the occurrence of adverse drug reactions in chronic non-inflammatory and autoimmune rheumatic diseases. Symptomatic non-steroidal anti-inflammatory drugs, as well as disease-modifying drugs, are complicated by drop-outs (poor patient compliance) in a large percentage of patients. Even though intensive and careful monitoring is always clearly advisable, preliminary data suggest that typing of genes controlling the effects, metabolism and response of drugs might be of clinical utility to define the 'at-risk' genotype.

Original languageEnglish
Pages (from-to)1107-1116
Number of pages10
Issue number8
Publication statusPublished - Dec 2004


  • Azathioprine
  • COXIBs
  • Cyclophosphamide
  • Leflunomide
  • Methotrexate
  • NSAIDs
  • Pharmacogenetic
  • Pharmacogenomics
  • Rituxan
  • SNP
  • TNF-α blockers

ASJC Scopus subject areas

  • Genetics(clinical)
  • Pharmacology


Dive into the research topics of 'Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology'. Together they form a unique fingerprint.

Cite this